Fig. 4: Endothelial cell identity in the control or rapamycin-coated patches harvested from aorta arterioplasty or IVC venoplasty, day 14.
From: The application of tissue-engineered fish swim bladder vascular graft
a First row, Photograph of immunohistochemistry stained for CD31; second row, and photograph of the immunofluorescence merge of CD34 (red) and DAPI (blue) of the neointima; scale bar, 100 μm, n = 3. b, c Bar graphs showing neointimal reendothelialization of the arterioplasty (p = 0.8744) and venoplasty (p = 0.9037), day 14; t-test; n = 3. d, e Bar graphs showing the neointimal CD34-positive cell coverage in the arterioplasty (p = 0.8416) and venoplasty (p = 0.9465) model at day 14, t-test, n = 3. f, g Bar graphs showing the adventitial CD31-positive cells in the arterioplasty (*p = 0.0096) and venoplasty (*p = 0.0065), day 14; t-test; n = 3. h, i Bar graphs showing the percentages of neointimal Ephrin-B2 (p = 0.6893) and dll-4 (p = 0.8925) positive cells in the arterioplasty, day 14; t-test; n = 3. j, k Bar graphs showing the percentages of neointimal Eph-B4 (p = 0.4463) and COUP-TFII (p = 0.2304) positive cells in the venoplasty, day 14; t-test; n = 3. Data are expressed as mean ± s.e.m.
